Ultragenyx Hit With Class Action Over Setrusumab Trial Data Misrepresentations
Class action filed against Ultragenyx ($RARE) alleging misrepresented setrusumab trial data. Investors purchasing August 2023-December 2025 may recover damages.
RAREsecurities fraudclass action lawsuit
